检索结果-南通市图书馆

Analge.ic e.ficacy of Parace.vical Block for Manual Vacuum Aspiration of Incomple.e.Abortions: A Randomize. Controlle. Trial

引用

Ope. Journal of Obste.rics and Gyne.ology 2021年第8期11卷 955-972页

作者： e.undayo O. Aye.busi Akintunde.O. Fe.intola Akinyosoye.D. Ajiboye.Ayode.e.Idowu Tope.O. Okunola Michae. S. Archibong olajide e. babalola Oluse.un O. Bade.oko More.ise.O. Loto De.artme.t of Obste.rics Gynaecology and Perinatology Faculty of Clinical Sciences College of Health Sciences Obafemi Awolowo University Ile Ife Osun State. Nigeria De.artme.t of Obste.rics and Gynae.ology State Specialist Hospital Ikare Akoko Ondo State Nigeria De.artme.t of Obste.rics and Gynae.ology Ekiti State University Teaching Hospital Ado-Ekiti Ekiti State Nigeria

Introduction: Pain control during Manual Vacuum Aspiration is one.of the.most important aspe.ts of postabortion care. This study asse.se. the.analge.ic e.ficacy, re.uire.e.t for additional analge.ia, and ove.all satis... 详细信息

Introduction: Pain control during Manual Vacuum Aspiration is one of the most important aspects of postabortion care. This study assessed the analgesic efficacy, requirement for additional analgesia, and overall satisfaction using Paracervical blocks of 1% lignocaine compare with normal saline as placebo among women undergoing manual vacuum aspiration for incomplete abortion in OAUTHC, Ile-Ife. Methods: This was a double blind randomized controlled trial that occurred between January 2019 and February 2020. We randomized one hundred and twenty eligible women equally into 2 groups. Group A received paracervical block using 1% lignocaine while those in group B received paracervical block using normal saline as placebo. We obtained ethical clearance from the Ethics and Research Committee of the hospital. Preoperatively, we obtained relevant data and evaluated the degree of anxiety and pain on a visual analog scale (VAS). Intraoperative pain was evaluated from 2 viewpoints: that of the external observer on a 0 - 4 scale and that of the patient scale of 0 - 10 in the immediate postoperative period, followed by overall satisfaction at the point of discharge. We analyzed the data using SPSS version 20. Paired T test, independent T test e."font-family:Ve.dana;">Chi square.

关键词： Postabortion Care Pain Place.o Parace.vical Block

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Assay de.e.opme.t for de.e.mination of DZ2002, a ne. re.e.sible.SAHH inhibitor, and its acid me.abolite.DZA in blood and application to rat pharmacokine.ic study

引用

Journal of Pharmace.tical Analysis 2019年第1期9卷 25-33页

作者： We.we. Jia Jing Li Fe.fe. Du Yan Sun Fang Xu Fe.gqing Wang olajide e.Olale.e.Danghui Che. We. Tang Jianping Zuo Chuan Li State.Ke. Laboratory of Drug Re.e.rch Shanghai Institute of Materia Medica Chinese Academy of Sciences Unive.sity of Chine.e.Acade.y of Scie.ce. Chinese Academy of Sciences Fudan Unive.sity Shanghai Cance. Ce.te.

Me.hyl(S)-4-(6-amino-9 H-purin-9-yl)-2-hydroxybutanoate.DZ2002) is a pote.t re.e.sible.inhibitor of S-ade.osyl-L-homocyste.ne.hydrolase.SAHH). Due.to its e.te. structure. DZ2002 is rapidly hydrolyze. in rat blood to 4-(6-amino-9 H-purin-9-yl)-2-hydroxybutyric acid(DZA) during and afte. blood sampling from rats; this hampe.s accurate.de.e.mination of the.circulating DZ2002 and its acid me.abolite.DZA in rats. To this e.d, a me.hod for de.e.mining the.blood conce.trations of DZ2002 and DZA in rats was de.e.ope. by using me.hanol to imme.iate.y de.ctivate.blood carboxyle.te.ase. during sampling. The.ne.ly de.e.ope. bioanalytical assay posse.se. favorable.accuracy and pre.ision with lowe. limit of quantification of 31 nM for DZ2002 and DZA. This validate. assay was applie. to a rat pharmacokine.ic study of DZ2002. Afte. oral administration, DZ2002 was found to be.e.te.sive.y conve.te. into DZA. The.le.e. of syste.ic e.posure.to DZ2002 was significantly lowe. than that of DZA. The.appare.t oral bioavailability of DZ2002 was 90%–159%. The.me.n te.minal half-live. of DZ2002 and DZA we.e.0.3–0.9 and 1.3–5.1 h, re.pe.tive.y. The.sample.pre.aration me.hod illustrate. he.e.may be.adopte. for de.e.mination of othe. circulating e.te. drugs and the.r acid me.abolite. in rode.ts.

关键词： S-ade.osyl-L-homocyste.ne hydrolase DZ2002 Carboxyle.te.ase. Pharmacokine.ics

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

中药多成分药代动力学:发现与中药安全性和有效性关联的物质并揭示其药代特征

引用

药学学报 2021年第9期56卷 2426-2446页

作者：李川程晨贾伟伟杨军令余玄 olajide e.OLALe.e 中国科学院上海药物研究所新药研究国家重点实验室上海201203

中医药对中华民族健康和国家稳定发挥了重要作用,揭示决定中药有效性和安全性的物质是推进中药现代化的一项重要工作。对于化学组成复杂的中药,可通过开展多成分药代研究,根据给药后中药成分能否以某种形式被机体利用产生显著的体内暴露... 详细信息

中医药对中华民族健康和国家稳定发挥了重要作用,揭示决定中药有效性和安全性的物质是推进中药现代化的一项重要工作。对于化学组成复杂的中药,可通过开展多成分药代研究,根据给药后中药成分能否以某种形式被机体利用产生显著的体内暴露(以成分原形和/或代谢物形式),选拔出用于考察药效活性的中药物质,研究物质产生疗效的体内过程和药代特征,由此为揭示决定中药药效作用的物质创造条件。此外,这类多成分药代研究还可用于揭示与中药不良反应或联合用药风险关联的中药物质。经过十多年的努力,中药多成分药代研究在理论、方法、技术、应用上已取得突破,成为药代动力学的一个新分支。本文系统阐述了中药多成分药代动力学的研究方法、技术要求和分析技术,并用一类活性中药成分(三七的皂苷类成分)的研究和围绕一种已上市中药制剂(连花清瘟胶囊)的研究介绍了两类多成分药代研究实例,最后讨论了中药多成分药代研究的进一步发展。

关键词：中药多成分药代研究机体利用系统暴露肠腔暴露体内过程靶标到达

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

High de.re. of pharmacokine.ic compatibility e.ists be.we.n the.five.he.b me.icine.Xue.iJing and antibiotics come.icate. in se.sis care

引用

Acta Pharmace.tica Sinica B 2019年第5期9卷 1035-1049页

作者： Jian Li olajide e.Olale.e.Xuan Yu We.we. Jia Junling Yang Chuang Lu Songqiao Liu Jingjing Yu Xiaona Duan Yaya Wanga Kai Dong Rongrong He.Che. Che.g Chuan Li State.Ke. Laboratory of Drug Re.e.rch Shanghai Institute of Materia MedicaChinese Academy of Sciences Unive.sity of Chine.e.Acade.y of Scie.ce. De.artme.t of DMPK De.artme.t of Critical Care.Me.icine Zhongda HospitalSchool of MedicineSoutheast University School of Pharmacy University of Washington Tianjin Chase.un Pharmace.tical Co.Ltd.

Managing the.dysre.ulate. host re.ponse.to infe.tion re.ains a major challe.ge.in se.sis care. Chine.e.tre.tme.t guide.ine.re.omme.ds adding Xue.Bi Jing, a five.he.b me.icine. to antibioticbase. se.sis care. Although adding Xue.Bi Jing furthe. re.uce. 28-day mortality via modulating the.host re.ponse. pharmacokine.ic he.be.rug inte.action is a wide.y re.ognize. issue.that ne.ds to be.*** on our e.rlie. syste.atic che.ical and human pharmacokine.ic inve.tigations of Xue.Bi Jing, we.e.aluate. the.de.re. of pharmacokine.ic compatibility for Xue.Bi Jing/antibiotic combination base. on me.hanistic e.ide.ce.of inte.action risk. Conside.ing both Xue.Bi Jing-antibiotic and antibiotic-Xue.Bi Jing inte.action pote.tial, we.inte.rate. informatics-base. approach with e.pe.ime.tal approach and de.e.ope. a compound pair-base. me.hod for data proce.sing. To re.le.t clinical re.lity, we.se.e.te. for study Xue.Bi Jing compounds bioavailable.for drug inte.actions and 45 antibiotics commonly use. in se.sis care.in China. Base. on the.data of inte.acting with drug me.abolizing e.zyme. and transporte.s, no Xue.Bi Jing compound could pair, as pe.pe.rator, with the.antibiotics. Although some.antibiotics could,due.to the.r inhibition of uridine.50-diphosphoglucuronosyltransfe.ase.2 B15, organic anion transporte.s1/2 and/or organic anion-transporting polype.tide.1 B3, pair with se.kyunolide.I, tanshinol and salvianolic acid B, the.pote.tial inte.actions(re.ulting in incre.se. e.posure. are.like.y de.irable.due.to the.e.Xue.Bi Jing compounds’ low base.ine.e.posure.le.e.s. Inhibition of alde.yde.de.ydroge.ase.by 7 antibiotics probably re.ults in unde.irable.re.uction of e.posure.to protocate.huic acid from Xue.Bi ***, Xue.Bi Jing/antibiotic combination e.hibite. a high de.re. of pharmacokine.ic compatibility at clinically re.e.ant dose.. The.me.hodology de.e.ope. can be.applie. to inve.tigate.othe. drug combinations.

关键词： Xue.iJing Antibiotic Combination drug the.apy Se.sis Pharmacokine.ic compatibility He.b-drug inte.action

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Composition analysis of Compound She.hua Table.,a se.e.-he.b Chine.e.me.icine.for IgA ne.hropathy:e.aluation of analyte.capacity of the.assays

引用

Chine.e.Journal of Natural Me.icine. 2024年第2期22卷 178-192页

作者： ZHANG Haiyan WANG Qiuyue.WANG Jianan ZHANG Sichao JIA We.we. He.Ning XIA Xiaoyan WANG Ting LAI Liyu LI Jiaying DU Jing OLALe.e.olajide e.CHe. Xiangme. YANG Junling LI Chuan Graduate.School Tianjin University of Traditional Chinese MedicineTianjin 301617China State.Ke. Laboratory of Drug Re.e.rch Shanghai Institute of Materia MedicaChinese Academy of SciencesShanghai 201203China School of Pharmacy University of Chinese Academy of SciencesChinese Academy of SciencesBeijing 100049China De.artme.t of Ne.hrology First Medical Center of Chinese PLA General HospitalNephrology Institute of the Chinese People’s Liberation ArmyNational Key Laboratory of Kidney DiseasesNational Clinical Research Center for Kidney DiseasesBeijing Key Laboratory of Kidney Disease ResearchBeijing 100853China Zhongshan Institute.for Drug Discove.y Zhongshan 528400China Haihe.Laboratory of Mode.n Chine.e.Me.icine Tianjin 301617China

Compound She.hua Table.,a me.icine.comprising se.e. he.bs,is e.ploye. in tre.ting IgA *** study aime. to me.iculously analyze.its che.ical *** on a list of candidate.compounds,ide.tifie. through e.te.sive.lite.ature.re.ie. pe.tine.t to the.table.’s he.bal compone.ts,the.composition analysis e.taile. the.syste.atic ide.tification,characte.ization,and quantification of the.*** analyte.capacity of LC/e.I-MS-base. and GC/e.-MS-base. assays was *** ide.tifie. and characte.ize. constitue.ts we.e.quantifie. to de.e.mine.the.r conte.t le.e.s and we.e.ranke. base. on the.constitue.ts’daily dose..A total of 283 constitue.ts,classifie. into 12 distinct cate.orie.,we.e.ide.tifie. and characte.ize. in the.Compound She.hua *** constitue.ts e.hibite. conte.t le.e.s of 1−10982μg·g^(−1),with daily dose. of 0.01−395μmol·d^(−1).The.pre.ominant constitue.ts,with daily dose. of≥10μmol·d^(−1),include.nine.organic acids(citric acid,quinic acid,chloroge.ic acid,cryptochloroge.ic acid,gallic acid,ne.chloroge.ic acid,isochloroge.ic acid C,isochloroge.ic acid B,and linole.c acid),five.iridoids(spe.nue.he.ide.nue.he.oside.G13,nue.he.idic acid,se.oxyloganin,and se.ologanoside.,two monote.pe.e.glycoside.(pae.niflorin and albiflorin),a se.quite.pe.oid(curze.e.one.,a trite.pe.oid(ole.nolic acid),and a phe.yle.hanoid(salidroside..Additionally,the.e.we.e.83,126,and 55 constitue.ts de.e.te. in the.me.icine.with daily dose. of 1–10,0.1–1,and 0.01–0.1μmol·d^(−1),*** combination of the.LC/e.I-MS-base. and GC/e.-MS-base. assays de.onstrate. a comple.e.tary re.ationship in the.r analyte.capacity for de.e.ting the.constitue.ts pre.e.t in the.*** compre.e.sive.composition analysis e.tablishe. a solid foundation for furthe. pharmacological re.e.rch on Compound She.hua Table. and facilitate. the.quality e.aluation of this comple. he.bal me.icine.

关键词： Compound She.hua Table. Composition analysis Analyte.capacity

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Nove. assays for quality e.aluation of Xue.iJing:Quality variability of a Chine.e.he.bal inje.tion for se.sis manage.e.t

引用

Journal of Pharmace.tical Analysis 2022年第4期12卷 664-682页

作者： Xuan Yu We. Niu Ya-Ya Wang olajide e.Olale.e.Jia-Nan Wang Me.g-Yuan Duan Jun-Ling Yang Rong-Rong He.Zi-Xuan Chu Kai Dong Gui-Ping Zhang Chang-Xiao Liu Che. Che.g Chuan Li State.Ke. Laboratory of Drug Re.e.rch Shanghai Institute of Materia MedicaChinese Academy of SciencesShanghai201203China School of Pharmacy University of Chinese Academy of SciencesBeijing100049China Graduate.School Tianjin University of Traditional Chinese MedicineTianjin300193China Re.e.rch Institute Tianjin Chasesun Pharmaceutical Co.Ltd.Tianjin301700China State.Ke. Laboratory of Drug De.ive.y Te.hnology and Pharmacokine.ics and Tianjin Ke. Laboratory of Quality-Marke. of Traditional Chine.e.Me.icine. Tianjin Institute of Pharmaceutical ResearchTianjin300193China

Xue.iJing is an intrave.ous five.he.b inje.tion use. to tre.t se.sis in *** study aime. to de.e.op a liquid chromatography-tande. mass spe.trome.ry(LC-MS/MS)-or liquid chromatography-ultraviole.(LC-UV)-base. assay for quality e.aluation of *** de.e.opme.t involve. ide.tifying marke. constitue.ts to make.the.assay the.ape.tically re.e.ant and building a re.iable.one.point calibrator for monitoring the.various analyte. in *** marke. constitue.ts from the.five.he.bs we.e.se.e.te. base. on Xue.iJing's che.ical composition,pharmacokine.ics,and pharmacodynamics.A se.e.tivity te.t(for“similarity of re.ponse.)was de.e.ope. to ide.tify and minimize.inte.fe.e.ce.by nontarge. ***,an inte.ce.t te.t was de.e.ope. to fulfill“line.rity through ze.o”for e.ch analyte.absolute.ratio of inte.ce.t to C re.ponse.e.ne.ly de.e.ope. assays,we.analyze. sample. from 33 batche. of Xue.iJing,manufacture. ove. thre. ye.rs,and found small batch-to-batch variability in conte.ts of the.marke. constitue.ts(4.1%-14.8%),e.ce.t for se.kyunolide.I(26.5%).

关键词： Xue.iJing Chine.e.he.bal me.icine Quality variability Quality marke. One.point calibration

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

白藜芦醇潜在的有益健康作用:药代动力学带来的困惑

引用

中国临床药理学与治疗学 2021年第8期26卷 931-954页

作者：王亚亚褚子璇杨军令 olajide e.Olale.e.贺容容李木子程晨李川天津中医药大学研究生院天津301617 中国科学院上海药物研究所新药研究国家重点实验室上海201203 中国科学院大学北京100049

白藜芦醇(Re.ve.atrol,3,5,4'-三羟基-反式-二苯乙烯)最早在植物白藜芦(Ve.atrum grandiflorum ***)的根中被发现。白藜芦醇引起关注最初与“法国悖论”有关,该化合物不仅存在于红葡萄酒中,而且还展现出与红葡萄酒保护心血管作用相关的... 详细信息

白藜芦醇(Re.ve.atrol,3,5,4'-三羟基-反式-二苯乙烯)最早在植物白藜芦(Ve.atrum grandiflorum ***)的根中被发现。白藜芦醇引起关注最初与“法国悖论”有关,该化合物不仅存在于红葡萄酒中,而且还展现出与红葡萄酒保护心血管作用相关的生物活性。除保护心血管方面的作用外,白藜芦醇还在抗代谢性疾病、抗肿瘤和预防神经退行性疾病等方面表现出有益的作用。为了将这些潜在的有益健康作用向临床转化,人们对白藜芦醇开展了药代研究。本文作者从进入体循环的系统暴露和体内过程两个方面,总结了目前已知的口服后白藜芦醇的人体药代特征及围绕提高其系统暴露水平所做的多种尝试。然而,既有的药代动力学结果给白藜芦醇潜在作用的临床转化带来了困惑,包括:白藜芦醇展现有益健康的体外生物活性的物质形式(原形化合物)与口服后被机体利用的体内暴露形式(以代谢物为主)显著不同、药代研究测出的口服后白藜芦醇体内暴露水平明显低于其展现活性所需的浓度、根据白藜芦醇产生体内效应时所用的剂量推导出的体内暴露水平常明显低于研究其作用机制所用的浓度。为了更好地与白藜芦醇有益健康作用的研究相结合、促进其临床转化,作者建议从三方面进一步开展白藜芦醇的药代研究:(1)全面研究白藜芦醇代谢物的系统暴露、体内靶标到达及在靶细胞中的代谢,(2)研究口服后白藜芦醇的肠腔暴露,(3)开展红葡萄酒多成分药代研究。

关键词：白藜芦醇法国悖论有益健康作用药代动力学系统暴露体内过程肠道菌肠腔暴露

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Multiple.circulating saponins from intrave.ous She.mai inhibit OATP1Bs in vitro: pote.tial joint pre.ipitants of drug inte.actions

引用

中国药理学与毒理学杂志 2019年第10期 760-760页

作者： olajide e.OLALe.e.NIU We. DU Fe.-fe. WANG Fe.g-qing XU Fang Salisa PINTUSOPHON LU Jun-lan YANG Jun-ling LI Chuan State.Ke. Laboratory of Drug Re.e.rch Shanghai Institute of Materia Medica Chinese Academy of Sciences

She.mai, an intrave.ous inje.tion pre.are. from ste.me. Panax ginse.g roots（Hongshe.） and Ophiopogon japonicus roots（Maidong）, is use. as an add-on the.apy for coronary arte.y dise.se.and cance.;saponins are.its bioactive.constitue.ts. Since.many saponins inhibit human organic anion-transporting polype.tide.（OATP）1 B, this inve.tigation de.e.mine. the.inhibition pote.cie. of circulating She.mai saponins on the.transporte.s and the.joint pote.tial of the.e.compounds for She.mai-drug inte.action. Circulating saponins and the.r pharmacokine.ics we.e.characte.ize. in rats re.e.ving a 30 min infusion of She. Mai at 10 m L·kg-1. Inhibition of human OATP1 B1/1 B3 and rat Oatp1 b2 by the.individual saponins was inve.tigate. in vitro; the.compounds joint inhibition was also asse.se. in vitro and the.data was proce.se. using the.Chou-Talalay me.hod. Plasma prote.n binding was asse.se. by e.uilibrium dialysis. Altoge.he.,49 saponins in She.mai we.e.characte.ize. and grade. into: 10-100 μmol·d-1（compound dose. from She.mai;7 compounds）, 1-10 μmol · d-1（17 compounds）, ande. dosing, circulating saponins we.e.protopanaxadiol-type.ginse.oside. Rb1, Rb2, Rc, Rd, Ra1, Rg3,Ra2, and Ra3, protopanaxatriol-type.ginse.oside. Rg1,Re. Rg2, and Rf, and ginse.oside.Ro. The.protopanaxadioltype.ginse.oside. e.hibite. maximum plasma conce.trations of 2.1-46.6 μmol·L-1, plasma unbound fractions of 0.4%-1.0% and te.minal half-live. of 15.6-28.5 h（ginse.oside.Rg3, 1.9 h）, while.the.othe. ginse.oside. e.hibite. 0.1-7.7 μmol·L-1, 20.8%-99.2 %, and 0.2-0.5 h, re.pe.tive.y. The.protopanaxadiol-type.ginse.oside., ginse.oside. without any sugar attachme.t at C-20（e.ce.t ginse.oside.Rf）, and ginse.oside.Ro inhibite. OATP1B3 more.pote.tly(IC_50, 0.2-3.5 μmol · L-1) than the.othe. ginse.oside.(≥22.6 μmol·L-1). Inhibition of OATP1B1 by ginse.oside. was le.s pote.t than OATP1B3 inhibition. Ginse.oside. Rb1, Rb2, Rc, Rd, Ro, Ra1, Re. and Rg2 like

关键词： coronary arte.y dise.se.and cance. ginse.oside. She.mai

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

新型络氨酸激酶抑制剂安罗替尼的药物代谢动力学研究

新型络氨酸激酶抑制剂安罗替尼的药物代谢动力学研究

引用

第三届全国药物代谢动力学青年科学家论坛暨刘昌孝人才奖颁奖大会

作者：牛巍钟晨春杨军令李利陈峰程晨杜飞飞贾伟伟 OLALe.e.olajide e. 王凤清徐方李川中国科学院上海药物研究所新药研究国家重点实验室

目的:安罗替尼是一种口服络氨酸激酶抑制剂,本研究的目的是揭示其药代动力学特征,促进新药研发。方法:在大鼠、荷瘤小鼠及犬上考察安罗替尼的药动学特征和体内变化过程,结合体外手段研究其药代属性;在恶性实体瘤患者上开展Ⅰ期药代研究...

目的:安罗替尼是一种口服络氨酸激酶抑制剂,本研究的目的是揭示其药代动力学特征,促进新药研发。方法:在大鼠、荷瘤小鼠及犬上考察安罗替尼的药动学特征和体内变化过程,结合体外手段研究其药代属性;在恶性实体瘤患者上开展Ⅰ期药代研究;生物样品用液质联用技术分析。结果:口服给药后安罗替尼在大鼠及犬的肠道中吸收快,口服生物利用度分别为28-58%和41-77%,这与其膜通透性好且受肠道转运体影响小一致。由于在清除率上的差异,安罗替尼在大鼠和犬体内的半衰期分别为5.1和22.8h。安罗替尼从血中被清除的主要途径是由细胞色素P450酶介导的羟基化和脱烷基代谢,在人体中这些代谢反应主要由CYP3A酶介导。安罗替尼在大鼠及犬上的表观分布体积很大,在大鼠及荷瘤小鼠各组织中的浓度均高于相应的血药浓度。安罗替尼在各种属的血浆中结合率高,在人血浆中与白蛋白和α1-酸性糖蛋白均有高亲和性。安罗替尼在肿瘤患者体内半衰期为95-116 h。安罗替尼对人CYP3A4及CYP2C9有较强的体外抑制活性。结论:安罗替尼在多方面具有与其他络氨酸激酶抑制剂相似药代动力学特征,但其在人体内半衰期特别长。基于其药代特征而设计的"连二停一"给药方案使安罗替尼在Ⅱ/Ⅲ期临床试验中较好地展现了抗癌疗效和安全性。

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Pharmacokine.ics and Disposition of Circulating Iridoids and Organic Acids in Rats Intrave.ously Re.e.ving Re.uNing Inje.tion

Pharmacokinetics and Disposition of Circulating Iridoids and...

引用

中国药学会第十三届青年药学科研成果交流会

作者： Che. Che.g Fe.fe. Du Ke.Yu Fang Xu Fe.gqing Wang Li Li olajide e.Olale.e.Junling Yang Fe.g Che. Che.chun Zhong Qiongwe. Liu Jing Li Zhe.zhong Wang Chuan Li We. Xiao State.Ke. Laboratory of Drug Re.e.rch Shanghai Institute of Materia MedicaChinese Academy of Sciences Jiangsu Kanion Pharmace.tical Corporation

Re.uNing inje.tion,pre.are. from a combination of Garde.ia Jasminoide. fruits,Lonice.a japonica flowe. buds,and Arte.isia annua ae.ial part,is e.te.sive.y use. for tre.tme.t of viral uppe. re.piratory tract infe.tion in ***,organic acids,and flavonoids are.probably important for the.he.bal inje.tion be.ause.of the.r re.orte. pharmacological *** study was de.igne. to characte.ize.pharmacokine.ics and disposition of major circulating he.bal compounds in rats intrave.ously re.e.ving the.*** inje.tion was found to contain 19 iridoids（conte.t le.e.s,0.01-27.93 mM）,16 organic acids（0.04-19.06 mM）,and 11 flavonoids（＜0.08 mM）.Afte. dosing the.inje.tion,the.iridoids ge.iposide.se.ologanic acid,se.oxyloganin,ge.ipin-l-β-ge.tiobioside.ge.iposidic acid,swe.oside.and shanzhiside.and the.organic acids chloroge.ic acid,quinic acid,cryptochloroge.ic acid,and ne.chloroge.ic acid we.e.found to be.the.major circulating compounds with me.n e.imination half-live. of 0.2-0.9 hour,whe.e.s othe. plasma compounds we.e.at low e.posure.*** major circulating compounds e.hibite. small appare.t volume. of distribution（0.03-0.34 1/kg）.Most of the.iridoids we.e.e.iminate. pre.ominantly via re.al e.cre.ion of the.unchange. compounds,whe.e.s the.organic acids we.e.e.iminate. via me.hylation and sulfation and e.cre.e. into urine.as the.unchange. and me.abolize. *** me.hylate. me.abolite. also unde.we.t subse.ue.t conjugations be.ore.he.atobiliary and re.al *** vitro data sugge.te. that the.pre.e.ing me.abolism of the.organic acids in rats also occurre. in *** curre.t pharmacokine.ic re.e.rch could se.ve.as a crucial ste. in ide.tifying the.che.ical basis re.ponsible.for the.the.ape.tic action of Re.uNing inje.tion.

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：